ADVISORY, Dec. 5, 2013 (GLOBE NEWSWIRE) --
What:
Venaxis, Inc. [APPY], an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Steve Lundy, President and CEO, will ring the Closing Bell to celebrate the company's recent achievements as it advances the APPY1 Test toward potential FDA clearance and expands its commercial footprint in the EU. Venaxis™ remains on track to complete patient enrollment for its pivotal clinical study of the APPY1 Test in the United States at or around the end of 2013.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Friday, December 6, 2013 – 3:45 p.m. to 4:00 p.m. ET
Contact:
Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 375-2665
jrando@tiberend.com
NASDAQ MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaqomx.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.
Webcast:
A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx.
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Venaxis, Inc. [APPY]:
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries. For more information, visit www.venaxis.com.
About NASDAQ OMX Group:
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and approximately 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,300 listed companies with a market value of over $7 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.
-NDAQA-
